Fig. 8: The THR-β agonist RES inhibits ACBP/DBI and prevents Cushing’s syndrome.
From: Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome
a, The experimental schedule showing the treatment of female C57BL/6J mice with RES (0.033 mg ml−1 or vehicle control (control) per gavage). b,c, Plasma ACBP (b) and liver Acbp mRNA (c) were measured by ELISA and qRT–PCR, respectively (n = 6 per group; RU, relative units). d, The experimental schedule showing the treatment of mice with CORT (100 μg ml−1, p.o.) and RES (0.033 mg ml−1 in drinking water, p.o.) for 5 weeks. e,f, WAT Acbp mRNA (n = 5 per group) (e) and plasma ACBP (n = 9–10 per group) (f) were measured at the end of the fifth week in the indicated groups. g,h, The average food intake (n = 3 cages per group) (g) and body weight (n = 9–10 mice per group) (h) were monitored. P values refer to the comparison of areas under the curve. i, The heatmap shows the standardized deviations (z scores) of tissue weight relative to body weight and the quantification of various biochemical parameters across the treatment groups (n = 9, 10, 10 and 10 mice per group). Statistical comparisons were performed by pairwise (two-tailed) Wilcoxon test with false discovery rate (FDR) correction for multiple comparisons (P values are indicated). j–m, GTT (n = 9–10 mice per group) (j) and ITT (n = 9–10 mice per group) (l) was monitored in the indicated groups. P values refer to the comparison of areas under the curve (GTT (k) and ITT (m)). Statistical comparisons were performed by pairwise Wilcoxon tests with FDR correction for multiple comparison in the heatmaps. All dot plots depict means ± s.e.m. Arbitrary units, AU. The data in b and c were analysed by unpaired t-test (two tailed). The curves in g and h were longitudinally analysed with type II ANOVA and pairwise comparisons. The data in e, f, k and m were analysed using one-way ANOVA with Tukey correction. Created with BioRender.com.
